Abstract:The analysis of the molecular mechanisms governing multistep carcinogenesis became experimentally approachable since the identification and characterization in tumor cells of altered or activated versions of cellular genes (oncogenes) that normally control cell growth and differentiation. The activating mutations confer new properties to the oncogene products and should therefore be considered as gain of function mutations. In addition, the oncogenes appear to act as dominant genetic traits since they act also in the presence of the homologous wild-type allele. However, the concept of a dominance of the transformed phenotype has been challenged by early experiments with somatic cell hybrids which showed that the fusion of normal and malignant cells may suppress the tumorigenic phenotype. The suppression or reversion of the malignant phenotype by the introduction of a normal chromosome into a tumor cell line has lent support to the idea that a family of cellular genes are coding for factors capable to interact with the cell-growth control machinery. These genes seem to reconstitute the normal control of cell growth even in the presence of an activated oncogene. In addition, a two-mutation model has been proposed to explain the epidemiological and clinical features of childhood cancers. According to the model, the development of these malignancies can be caused by the loss or inactivation of both alleles of cellular genes, as suggested by the somatic cell hybrid experiments where the function of the inactivated genes is restored by the contribution of those derived from the normal parental cells. This family of genes is designated as onco-suppressor genes since their product is necessary for the normal regulated cell growth and is lacking or inactivated in malignant cells. At gene level they should be considered as recessive genetic traits, since the tumor phenotype appears when both alleles of an oncosuppressor gene are inactivated. The mutations affecting their normal functions belong to the type « loss of function ». The molecular analysis of retinoblastoma has led to the cloning and sequencing of the related onco-suppressor gene (RB gene) whose product displays the features of a gene-regulatory protein. In addition, a binding between the RB product and various viral onco-proteins (E1A, large T, E7) has been demonstrated, thus suggesting a mechanism of RB inactivation by which some DNA viruses can transform the host cell. Finally, the increasing availability of DNA markers, defining restriction fragment length polymorphisms, has led to the mapping of the loci of inherited predisposition for familial cancer syndromes such as MEN-1, VHL and NF-2 and to the extension to common cancers of the allele losses analysis that can reveal onco-suppressor gene inactivation. This indirect approach has suggested the occurrence of different onco-suppressor genes for sporadic breast, colonic and lung cancers, bladder carcinoma, germinal tumors of the testis and malignant melanoma. In particular, colonic cancer provides a significant example of a possible multistep scenario for carcinogenesis in humans in which activated oncogenes (e.g. ras) and inactivated putative onco-suppressor genes (on chromosome 17 and 18) coexist in the same cell.

Current Progress on Study of Tumor Suppressor Genes in Brain Tumors

Advances in the study of tumor suppressor genes in gliomas

Therapeutic Potential of Tumor Treating Fields for Malignant Brain Tumors

Characterization of tumor suppressors and oncogenes evaluated from TCGA cancers

Onco-Suppressor Genes in Human Cancer

Progress in the Molecular Biology Study of Brain Tumor Stem Cells

EPCO-51. FUNCTIONAL ANALYSIS OF REGULATORY MUTATIONS IN PEDIATRIC BRAIN TUMORS

Targeting Tumor Suppressor Genes for Cancer Therapy

Retraction Note: Genetic Alterations of the NRP/B Gene Are Associated with Human Brain Tumors

Targeting Tumor Suppressor Networks for Cancer Therapeutics

Regulating tumor suppressor genes: post-translational modifications

Current Tendency of Chemotherapy for Malignant Brain Tumor:Targeted Molecular Therapy

Tumor Suppressor MicroRNAs in Clinical and Preclinical Trials for Neurological Disorders

Progress on Regulatory T Cells and Tumor

[Establishment of Malignant Progression Associated Gene Expression Profiles in Human Brain Glioma].

Biological characterization of primary and recurrent brain tumor stem cells

Brain Tumor Networks in Diffuse Glioma

Tumor suppressor gene alterations in malignant gliomas: histopathological associations and prognostic evaluation

A Glance of p53 Functions in Brain Development, Neural Stem Cells, and Brain Cancer

Pten Negatively Regulates Neural Stem Cell Self-Renewal By Modulating G(0)-G(1) Cell Cycle Entry

Genetic and Clinical Characteristics of Genetic Tumor Syndromes in the Central Nervous System Cancers: Implications for Clinical Practice